Why the bargain the GOP and President Trump may be unraveling and more questions about Trump family business entanglements here and abroad
Food scares and drug scandals have raised serious concerns over the F.D.A.’s ability to regulate effectively. A look at the resources and direction at the Food and Drug Administration, and why some are hoping for significant changes under the next administration.
- Gardiner Harris Science reporter for "The New York Times"
- Alan Goldhammer, PhD Associate vice president for regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA)
- Dr. Sidney Wolfe Director of the Health Research Group at Public Citizen; editor of WorstPills.org
- Rep. Rosa DeLauro U.S. Congresswoman, representing Connecticut's 3rd district; chairwoman of the Agriculture-FDA Appropriations Subcommittee
- William Hubbard Former associate commissioner for the Food and Drug Administration; spokesperson for the Alliance for a Stronger FDA
Most Recent Shows
Reaction to this week's political shocks, why many conservatives are choosing to double down on Trump critics, and then, a conversation on the growing dis-union in America.
Political fallout from the dismissal of FBI director James Comey, how our government created racially segregated cities, and a young Palestinian's perspective on Mideast peace.
Washington Post reporter Dan Balz on covering President Trump and linguist Deborah Tannen on how women support each other with the words they use.